FDA Introduces New Framework to Advance Individualised Therapies for Ultra-Rare Diseases.

The U.S. Food and Drug Administration (FDA) today issued draft guidance for sponsors seeking full approval for targeted individualised therapies by generating substantial evidence of effectiveness and safety when randomised controlled trials are not feasible due to small patient populations. 

The initiative marks a major shift in how regulators evaluate treatments tailored to single patients or extremely small populations where traditional randomised clinical trials are often impossible. 

According to Towards Healthcare, the Hyper-Personalised Medicine Market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 3.71 trillion in 2026 to approximately USD 12.59 trillion by 2035, representing a compound annual growth rate (CAGR) of 14.55% from 2026 to 2035. Growth is driven by the increasing demand for advancements in precision medicine and the integration of artificial intelligence and big data analytics. It includes tailored therapies, advancements in gene and cell therapies, and rising government initiatives supporting personalised medicine. 

FDA Commissioner Marty Makary, M.D., M.P.H, said this guidance is a critical step the FDA is taking to tailor our regulatory approach to patients with ultra-rare conditions. 

Vinay Prasad, MD, MPH, Chief Medical and Scientific Officer at the FDA’s Centre for Biologics Evaluation and Research, called the framework a “revolutionary advance in regulatory science.” It is a novel regulatory concept allowing individualised therapies to demonstrate effectiveness through a scientifically supported mechanism of action. 

How Effectiveness Can be Demonstrated Without Large Trials 

The FDA acknowledges that individualised therapies are often involve extremely small patient populations. Under the new guidance, effectiveness may be demonstrated through multiple complementary forms of evidence, including: Well-characterised natural history data from untreated patients, Biomarkers that predict clinical benefit, Demonstration of successful target engagement or gene correction, and improvement in clinical outcomes. 

It emphasises that small studies must provide robust and scientifically credible evidence, minimising the likelihood that observed effects occurred by chance. 

A recent report by Towards Healthcare highlights that the Hyper-Personalised Medicine Market is witnessing growth due to the increasing demand for tailored treatments, leading to investments in new diagnostic tools and therapeutic platforms, offering more effective and personalised treatment options for patients.  

The North America region has been a significant market for hyper-personalized medicine, particularly in the United States, where substantial research and development in genomics, molecular diagnostics, and personalized medicines have taken place. 

Asia Pacific is witnessing a growing interest in hyper-personalised medicine, with countries like China, Japan, and South Korea investing in genomic research, molecular diagnostics, and precision medicine initiatives.